

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hansen; Bjorn Erik Confirmation No.:

Serial No.: 17/525248 Group No.:

Filing or 371(c) Date: November 12, 2021 Examiner:

Entitled: SEXUAL THERAPY FORMULATION AND METHOD OF TREATMENT

**THIRD-PARTY PRE-ISSUANCE SUBMISSION**

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application:

1. HALKITIS (2007) "Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context" Vol. 1(2): 139-147. American Journal of Men's Health.
2. McMURRAY (2007) "Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction" Vol. 3(6): 975-981. Therapeutics and Clinical Risk Management.
3. SMITH (2005) "Recreational Use and Misuse of Phosphodiesterase 5 Inhibitors" Vol. 45(1): 63-75. Journal of the American Pharmacists Association.
4. BAHJI (2019) "Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis" Vol. 96: 1-15. Progress in Neuropsychopharmacology & Biological Psychiatry.
5. OBLIVION (2003) "Viagra with MDMA for Erections" Retrieved 4 May 2014.  
<https://web.archive.org/web/20140504015737/https://erowid.org/experiences/exp.php?ID=27174>
6. VSJOE (2018) "Finally, I Was Also Able to Orgasm" Retrieved 8 February 2019.  
<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=11215>  
1
7. LINGAMYONI (2003) "Foxy Sextasy" Retrieved 7 June 2007.  
<https://web.archive.org/web/20070607024945/https://erowid.org/experiences/exp.php?ID=21223>
8. MOONDO (2014) "To Treat Premature Ejaculation" Retrieved 22 February 2019.  
<https://web.archive.org/web/20190222023609/https://erowid.org/experiences/exp.php?ID=10404>  
8
9. Int'l Pat. App. Pub. No. WO/2020/006606 "A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME" (Published January 9, 2020)

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 17/525248 Pending Claims	References
<p><b>1.</b> A sexual therapy formulation for treatment of a patient suffering from some degree of erectile dysfunction as well as low or reduced libido, said formulation comprising: an erection enhancement component comprising one or more of sildenafil citrate, vardenafil hydrochloride, tadalafil, and avanafil; a libido stimulation component comprising one or more of dehydroepiandrosterone, testosterone, dihydrotestosterone, L-arginine, L-citrulline, Vitamin E, fenugreek, ginseng, maca, yohimbine, 3,4-methylenedioxymethamphetamine, an R(-) isomer of 3,4-methylenedioxymethamphetamine, an S(+) isomer of 3,4-methylenedioxymethamphetamine, and a racemic mixture of 3,4-methylenedioxymethamphetamine; and a synergistic effect produced from said erection enhancement component combined with said libido stimulation component allows the patient to obtain and maintain an</p>	<p>1. HALKITIS (2007) "Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context" Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> "Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate)."</p> <p>From <b>page 139</b> "Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange."</p> <p>From <b>page 144</b> "Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with age</b> and (b) limited access to health care and medications for minorities in general."</p> <p>2. McMURRAY (2007) "Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction" Vol. 3(6): 975-981. Therapeutics and Clinical Risk Management.</p> <p>From <b>page 975</b> "In March 1998, the US Food and Drug Administration (FDA) approved <b>sildenafil citrate (Viagra®</b>, Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998)."</p> <p>4. BAHJI (2019) "Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis" Vol. 96: 1-15. Progress in Neuropsychopharmacology &amp; Biological Psychiatry.</p> <p>From <b>page 12</b></p>

erection thus permitting the patient to engage in intimate sexual activity as well providing the patient with the desire to engage in intimate sexual activity.

**Appendix 8. Properties of MDMA table**

Category	MDMA-Induced state
Mood/Affect	Mild euphoria; anxiolytic; fear extinction; enhanced perception of feelings; increased tolerance of affect
Cognition/Memory	Boosted creativity and imagination; increased contemplativeness; enhanced recall and tolerance of traumatic memory
Attachment & interpersonal behaviour	Reduced social fears and defensiveness; improved social approach behaviours; enhanced empathy, openness, trust, feelings of connection; increased need for touch
Self	Boosted self-esteem and self-acceptance
Body	Analgesia; muscle relaxation; enhanced libido and sensuality

9. Int'l Pat. App. Pub. No. WO/2020/006606 "A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME" (Published January 9, 2020)

From **Abstract** "The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.**"

From **claim 1** "A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**"

From **claim 3** "The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **vardenafil**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil."

From **claim 4** "The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants."

	<p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided a <b>pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>2.</b> The sexual therapy formulation as recited in claim 1, wherein said erection enhancement component comprises an amount of sildenafil citrate.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with age</b> and (b) limited access to health care and medications for minorities in general.”</p>

2. McMURRAY (2007) “Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction” Vol. 3(6): 975–981. Therapeutics and Clinical Risk Management.

From **page 975** “In March 1998, the US Food and Drug Administration (FDA) approved **sildenafil citrate (Viagra®**, Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998).”

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction** and premature ejaculation.”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: avanafil, iodenafil, mirodenafil, **sildenafil**, tadalafil, vardenafil, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

From **claim 10** “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: **3,4-methylenedioxymethamphetamine**, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”

From **page 2** “According to an embodiment of the invention, there is provided **a pharmaceutical composition** in a pharmaceutically acceptable

	<p>vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>3.</b> The sexual therapy formulation as recited in claim 2, wherein a unit dosage of said formulation comprises a therapeutically effective amount of said erection enhancement component comprising sildenafil citrate.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4 methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with age</b> and (b) limited access to health care and medications for minorities in general.”</p> <p>2. McMURRAY (2007) “Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction” Vol. 3(6): 975–981. Therapeutics and Clinical Risk Management.</p> <p>From <b>page 975</b> “In March 1998, the US Food and Drug Administration (FDA) approved <b>sildenafil citrate (Viagra®</b>, Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998).”</p> <p>9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)</p>

	<p>From <b>Abstract</b> “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. <b>The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.</b>”</p> <p>From <b>claim 1</b> “A <b>pharmaceutical composition in a pharmaceutically acceptable vehicle</b>, the pharmaceutical composition comprising a physiologically effective, non- priapismic, <b>dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.</b>”</p> <p>From <b>claim 3</b> “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: avanafil, iodenafil, mirodenafil, <b>sildenafil</b>, tadalafil, vardenafil, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”</p> <p>From <b>claim 4</b> “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”</p> <p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided <b>a pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>4.</b> The sexual therapy formulation as recited in claim 3, wherein said therapeutically effective amount of sildenafil citrate is</p>	<p><b>3.</b> SMITH (2005) “Recreational Use and Misuse of Phosphodiesterase 5 Inhibitors” Vol. 45(1): 63-75. Journal of the American Pharmacists Association.</p> <p>From <b>page 66</b> “<b>Sildenafil citrate</b> is marketed in the United States as <b>25, 50, and 100 mg</b> tablets.11 The drug is sometimes referred to as “vitamin V,”</p>

<p>about 20 milligrams to about 100 milligrams.</p>	<p>and slang terms pertaining to its recreational use include “hammerheading” and “sextasy” (<b>use in conjunction with methylenedioxyamphetamine [MDMA], ecstasy</b>); and “tina,” (use in conjunction with methamphetamine).<sup>16</sup> Also known as a “thrill pill,” sildenafil has been sold on school and college campuses and at parks, with subsequent consumption at clubs and raves.<sup>17</sup> It is often purchased for \$25–\$30 on the black market.”</p> <p>5. OBLIVION (2003) “Viagra with MDMA for Erections” Retrieved 4 May 2014.  <a href="https://web.archive.org/web/20140504015737/https://erowid.org/experiences/exp.php?ID=27174">https://web.archive.org/web/20140504015737/https://erowid.org/experiences/exp.php?ID=27174</a></p> <p>“Ultimately, the dosage which you will require for your body is largely dependent on your health and your age. It is best to initially <b>start off with a dose of around 10 to 25 mgs. of Viagra, and then add an additional 10 to 25 mgs. for each roll</b> until you have found your ideal dosage.”</p>
<p>5. The sexual therapy formulation as recited in claim 1, wherein said libido stimulation component comprises an amount of 3,4-methylenedioxyamphetamine, said R(-) isomer of 3,4-methylenedioxyamphetamine, said S(-) isomer of 3,4-methylenedioxyamphetamine, and/or said racemic mixture of 3,4-methylenedioxyamphetamine.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxyamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with age</b> and (b) limited access to health care and medications for minorities in general.”</p>



4. BAHJI (2019) "Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis" Vol. 96: 1-15. Progress in Neuropsychopharmacology & Biological Psychiatry.

From page 12

Appendix 8. **Properties of MDMA** table

Category	MDMA-Induced state
Mood/Affect	Mild euphoria; anxiolytic; fear extinction; enhanced perception of feelings; increased tolerance of affect
Cognition/Memory	Boosted creativity and imagination; increased contemplativeness; enhanced recall and tolerance of traumatic memory
Attachment & interpersonal behaviour	Reduced social fears and defensiveness; improved social approach behaviours; enhanced empathy, openness, trust, feelings of connection; increased need for touch
Self	Boosted self-esteem and self-acceptance
Body	Analgesia; muscle relaxation; enhanced libido and sensuality

6. The sexual therapy formulation as recited in claim 5, wherein a unit dosage of said formulation comprises a therapeutically effective amount of said libido stimulation component comprising 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, and/or said racemic mixture of 3,4-methylenedioxymethamphetamine.

4. BAHJI (2019) "Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis" Vol. 96: 1-15. Progress in Neuropsychopharmacology & Biological Psychiatry.

From page 12

Appendix 8. **Properties of MDMA** table

Category	MDMA-Induced state
Mood/Affect	Mild euphoria; anxiolytic; fear extinction; enhanced perception of feelings; increased tolerance of affect
Cognition/Memory	Boosted creativity and imagination; increased contemplativeness; enhanced recall and tolerance of traumatic memory
Attachment & interpersonal behaviour	Reduced social fears and defensiveness; improved social approach behaviours; enhanced empathy, openness, trust, feelings of connection; increased need for touch
Self	Boosted self-esteem and self-acceptance
Body	Analgesia; muscle relaxation; enhanced libido and sensuality

	<p>9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)</p> <p>From <b>Abstract</b> “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. <b>The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.</b>”</p> <p>From <b>claim 1</b> “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, <b>dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.</b>”</p> <p>From <b>claim 3</b> “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: <b>avanafil</b>, iodenafil, mirodenafil, <b>sildenafil</b>, <b>tadalafil</b>, <b>vardenafil</b>, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”</p> <p>From <b>claim 4</b> “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”</p> <p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypyrovalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided <b>a pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p>7. The sexual therapy formulation as recited</p>	<p>6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.</p>

in claim 6, wherein said therapeutically effective amount of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, and/or said racemic mixture of 3,4-methylenedioxymethamphetamine, is about 30 milligrams to about 125 milligrams.

<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=112151>

DOSE:				
T+ 0:00	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:00	80 mg	oral	MDMA	(powder / crystals)
T+ 3:00	80 mg	oral	MDMA	(powder / crystals)

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.  
<https://web.archive.org/web/20070607024945/https://erowid.org/experiences/exp.php?ID=21223>

DOSE : T+				
T+ 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DiPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.  
<https://web.archive.org/web/20190222023609/https://erowid.org/experiences/exp.php?ID=104048>

DOSE:				
	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

8. The sexual therapy formulation as recited in claim 4, wherein said libido stimulation component comprises an amount of 3,4-methylenedioxymethamphetamine, said R(-)

6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.  
<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=112151>

isomer of 3,4-methylenedioxyamphetamine, said S(+)-isomer of 3,4-methylenedioxyamphetamine, and/or said racemic mixture of 3,4-methylenedioxyamphetamine.

DOSE:	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 0:00	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:00	80 mg	oral	MDMA	(powder / crystals)
T+ 3:00	80 mg	oral	MDMA	(powder / crystals)

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.  
<https://web.archive.org/web/20070607024945/https://erowid.org/experience/s/exp.php?ID=21223>

**Foxy Sextasy**  
MDMA, 5MeO-DiPT, & Sildenafil (Viagra)  
by Lingamyoni

DOSE : T+ 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DiPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.  
<https://web.archive.org/web/20190222023609/https://erowid.org/experience/s/exp.php?ID=104048>

DOSE:	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

9. The sexual therapy formulation as recited in claim 8, wherein a unit dosage of said formulation comprises a therapeutically effective amount of said libido stimulation

6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.  
<https://web.archive.org/web/20190208014713/https://erowid.org/experience/s/exp.php?ID=112151>

component comprising 3,4-methylenedioxyamphetamine, said R(-) isomer of 3,4-methylenedioxyamphetamine, said S(+) isomer of 3,4-methylenedioxyamphetamine, and/or said racemic mixture of 3,4-methylenedioxyamphetamine.

DOSE:				
T+ 0:00	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:00	80 mg	oral	MDMA	(powder / crystals)
T+ 3:00	80 mg	oral	MDMA	(powder / crystals)

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.  
<https://web.archive.org/web/20070607024945/https://erowid.org/experience/s/exp.php?ID=21223>

DOSE:	T+			
125 mg	0:00	oral	MDMA (Ecstasy)	(powder / crystals)
50 mg	0:00	oral	Pharms - Sildenafil	(pill / tablet)
25 mg	1:30	oral	5-MeO-DiPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.  
<https://web.archive.org/web/20190222023609/https://erowid.org/experience/s/exp.php?ID=104048>

DOSE:				
3 glasses		oral	Alcohol - Beer/Wine	
60 mg		oral	MDMA	(powder / crystals)
60 mg		oral	MDMA	(powder / crystals)
25 mg		oral	Pharms - Sildenafil	(pill / tablet)
3 glasses		oral	Alcohol - Beer/Wine	
50 mg		oral	Pharms - Sildenafil	(pill / tablet)

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition

salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.**”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **vardenafil**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

From **claim 10** “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: **3,4-methylenedioxymethamphetamine**, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /V-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”

From **page 2** “According to an embodiment of the invention, there is provided **a pharmaceutical composition** in a pharmaceutically acceptable vehicle, **the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent** or a pharmaceutically acceptable addition salt thereof **and a physiologically effective dose of an orgasm-delaying agent** or a pharmaceutically acceptable addition salt thereof.”

**10.** The sexual therapy formulation as recited in claim 9, wherein said therapeutically effective amount of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+)

6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.  
<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=112151>

DOSE:	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 0:00	80 mg	oral	MDMA	(powder / crystals)
T+ 1:00	80 mg	oral	MDMA	(powder / crystals)
T+ 3:00	80 mg	oral	MDMA	(powder / crystals)

isomer of 3,4-methylenedioxyamphetamine, and/or said racemic mixture of 3,4-methylenedioxyamphetamine, is about 30 milligrams to about 125 milligrams.

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.  
<https://web.archive.org/web/20070607024945/https://erowid.org/experience/exp.php?ID=21223>

The screenshot shows a browser window with the URL <https://erowid.org/experiences/exp.php?ID=21223>. The page title is "Foxy Sextasy" by Lingamyoni, containing MDMA, 5MeO-DiPT, & Sildenafil (Viagra). A table lists the following dosing schedule:

DOSE: T 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DiPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.  
<https://web.archive.org/web/20190222023609/https://erowid.org/experience/exp.php?ID=104048>

The screenshot shows a browser window with the URL <https://erowid.org/experiences/exp.php?ID=104048>. The page title is "To Treat Premature Ejaculation" by Moondo. A table lists the following dosing schedule:

DOSE:	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.**”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-**

	<p><b>inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.”</b></p> <p>From <b>claim 3</b> “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: <b>avanafil</b>, iodenafil, mirodenafil, <b>sildenafil</b>, <b>tadalafil</b>, <b>vardeafil</b>, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”</p> <p>From <b>claim 4</b> “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”</p> <p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypyrovalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided <b>a pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>11.</b> A sexual therapy formulation for treatment of a patient suffering from some degree of erectile dysfunction as well as low or reduced libido, said formulation comprising: an erection enhancement component selected from the group consisting of sildenafil citrate, vardenafil hydrochloride, tadalafil, and avanafil; a libido stimulation component selected from the group consisting of</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of</p>



dehydroepiandrosterone, testosterone, dihydrotestosterone, L-arginine, L-citrulline, Vitamin E, fenugreek, ginseng, maca, yohimbine, 3,4-methylenedioxymethamphetamine, an R(-) isomer of 3,4-methylenedioxymethamphetamine, an S(+) isomer of 3,4-methylenedioxymethamphetamine, and a racemic mixture of 3,4-methylenedioxymethamphetamine; and a synergistic effect produced from said erection enhancement component combined with said libido stimulation component allows the patient to obtain and maintain an erection thus permitting the patient to engage in intimate sexual activity as well providing the patient with the desire to engage in intimate sexual activity.

color, especially Black men. Furthermore, **age is strongly related to the behavior of combining sildenafil with certain club drugs**, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) **increasing rates of erectile dysfunction associated with age** and (b) limited access to health care and medications for minorities in general.”

2. McMURRAY (2007) “Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction” Vol. 3(6): 975–981. Therapeutics and Clinical Risk Management.

From **page 975** “In March 1998, the US Food and Drug Administration (FDA) approved **sildenafil citrate (Viagra®**, Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998).”

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction** and premature ejaculation.”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **vardenafil**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

	<p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided a <b>pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>12.</b> The sexual therapy formulation as recited in claim 11, wherein said erection enhancement component consists of an amount of sildenafil citrate.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with age</b> and (b) limited access to health care and medications for minorities in general.”</p>

	<p>2. McMURRAY (2007) “Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction” Vol. 3(6): 975–981. Therapeutics and Clinical Risk Management.</p> <p>From <b>page 975</b> “In March 1998, the US Food and Drug Administration (FDA) approved <b>sildenafil citrate (Viagra®</b>, Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998).”</p>
<p><b>13.</b> The sexual therapy formulation as recited in claim 12, wherein a unit dosage of said formulation comprises a therapeutically effective amount of said erection enhancement component consisting of sildenafil citrate.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4 methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with age</b> and (b) limited access to health care and medications for minorities in general.”</p> <p>2. McMURRAY (2007) “Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction” Vol. 3(6): 975–981. Therapeutics and Clinical Risk Management.</p> <p>From <b>page 975</b> “In March 1998, the US Food and Drug Administration (FDA) approved <b>sildenafil citrate (Viagra®</b>, Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998).”</p>

	<p>9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)</p> <p>From <b>Abstract</b> “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. <b>The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction</b> and premature ejaculation.”</p> <p>From <b>claim 1</b> “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, <b>dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.</b>”</p> <p>From <b>claim 3</b> “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: <b>avanafil</b>, iodenafil, mirodenafil, <b>sildenafil</b>, <b>tadalafil</b>, <b>vardenafil</b>, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”</p> <p>From <b>claim 4</b> “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”</p> <p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypyrovalerone, methylphenidate, nicotine, /V-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided <b>a pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>14.</b> The sexual therapy formulation as recited in claim 13, wherein</p>	<p>3. SMITH (2005) “Recreational Use and Misuse of Phosphodiesterase 5 Inhibitors” Vol. 45(1): 63-75. Journal of the American Pharmacists Association.</p>

<p>said therapeutically effective amount of sildenafil citrate is about 20 milligrams to about 100 milligrams.</p>	<p>From <b>page 66</b> “<b>Sildenafil citrate</b> is marketed in the United States as <b>25, 50, and 100 mg</b> tablets.<sup>11</sup> The drug is sometimes referred to as “vitamin V,” and slang terms pertaining to its recreational use include “hammerheading” and “sextasy” (<b>use in conjunction with methylenedioxymethamphetamine [MDMA], ecstasy</b>); and “tina,” (use in conjunction with methamphetamine).<sup>16</sup> Also known as a “thrill pill,” sildenafil has been sold on school and college campuses and at parks, with subsequent consumption at clubs and raves.<sup>17</sup> It is often purchased for \$25–\$30 on the black market.”</p> <p>5. OBLIVION (2003) “Viagra with MDMA for Erections” Retrieved 4 May 2014.  <a href="https://web.archive.org/web/20140504015737/https://erowid.org/experiences/exp.php?ID=27174">https://web.archive.org/web/20140504015737/https://erowid.org/experiences/exp.php?ID=27174</a></p> <p>“Ultimately, the dosage which you will require for your body is largely dependent on your health and your age. It is best to initially <b>start off with a dose of around 10 to 25 mgs. of Viagra</b>, and <b>then add an additional 10 to 25 mgs. for each roll</b> until you have found your ideal dosage.”</p>
<p><b>15.</b> The sexual therapy formulation as recited in claim 11, wherein said libido stimulation component consists of an amount of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, or said racemic mixture of 3,4-methylenedioxymethamphetamine.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) <b>increasing rates of erectile dysfunction associated with</b></p>

age and (b) limited access to health care and medications for minorities in general.”

4. BAHJI (2019) “Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis" Vol. 96: 1-15. Progress in Neuropsychopharmacology & Biological Psychiatry.

From page 12

**Appendix 8. Properties of MDMA table**

Category	MDMA-Induced state
Mood/Affect	Mild euphoria; anxiolytic; fear extinction; enhanced perception of feelings; increased tolerance of affect
Cognition/Memory	Boosted creativity and imagination; increased contemplativeness; enhanced recall and tolerance of traumatic memory
Attachment & interpersonal behaviour	Reduced social fears and defensiveness; improved social approach behaviours; enhanced empathy, openness, trust, feelings of connection; increased need for touch
Self	Boosted self-esteem and self-acceptance
Body	Analgesia; muscle relaxation; enhanced libido and sensuality

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction** and premature ejaculation.”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

	<p>From <b>claim 3</b> “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: <b>avanafil</b>, iodenafil, mirodenafil, <b>sildenafil</b>, <b>tadalafil</b>, <b>ildenafil</b>, <b>wardenafil</b>, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”</p> <p>From <b>claim 4</b> “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”</p> <p>From <b>claim 10</b> “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: <b>3,4-methylenedioxymethamphetamine</b>, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /V-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”</p> <p>From <b>page 2</b> “According to an embodiment of the invention, there is provided a <b>pharmaceutical composition</b> in a pharmaceutically acceptable vehicle, <b>the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent</b> or a pharmaceutically acceptable addition salt thereof <b>and a physiologically effective dose of an orgasm-delaying agent</b> or a pharmaceutically acceptable addition salt thereof.”</p>
<p><b>16.</b> The sexual therapy formulation as recited in claim 15, wherein a unit dosage of said formulation comprises a therapeutically effective amount of said libido stimulation component consisting of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, or said racemic mixture of 3,4-methylenedioxymethamphetamine.</p>	<p>1. HALKITIS (2007) “Sildenafil (Viagra) and Club Drug Use in Gay and Bisexual Men: The Role of Drug Combinations and Context” Vol. 1(2): 139-147. American Journal of Men's Health.</p> <p>From <b>page 139</b> “Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, <b>sildenafil [Viagra]</b>) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4-methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate).”</p> <p>From <b>page 139</b> “Of particular importance is the fact that <b>use of club drugs in combination with sildenafil is strongly associated with circuit and sex parties</b>, where a centerpiece of these environments focuses on sexual exchange.”</p> <p>From <b>page 144</b> “Specifically, the recreational <b>use of sildenafil in combination with the club drugs</b> included in this study (cocaine, GHB, ketamine, <b>MDMA</b>, methamphetamine) is less likely to occur among men of color, especially Black men. Furthermore, <b>age is strongly related to the behavior of combining sildenafil with certain club drugs</b>, with older men in our sample more likely to engage in this behavior than their younger</p>

counterparts. The fact that age and race were identified to be significant factors for the prediction of sildenafil use may be influenced by two conditions: (a) **increasing rates of erectile dysfunction associated with age** and (b) limited access to health care and medications for minorities in general.”

4. BAHJI (2019) “Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis" Vol. 96: 1-15. Progress in Neuropsychopharmacology & Biological Psychiatry.

From **page 12**

**Appendix 8. Properties of MDMA table**

Category	MDMA-Induced state
Mood/Affect	Mild euphoria; anxiolytic; fear extinction; enhanced perception of feelings; increased tolerance of affect
Cognition/Memory	Boosted creativity and imagination; increased contemplativeness; enhanced recall and tolerance of traumatic memory
Attachment & interpersonal behaviour	Reduced social fears and defensiveness; improved social approach behaviours; enhanced empathy, openness, trust, feelings of connection; increased need for touch
Self	Boosted self-esteem and self-acceptance
Body	Analgesia; muscle relaxation; enhanced libido and sensuality

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction** and premature ejaculation.”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a



physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **vardenafil**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

From **claim 10** “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: **3,4-methylenedioxymethamphetamine**, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /V-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”

From **page 2** “According to an embodiment of the invention, there is provided **a pharmaceutical composition** in a pharmaceutically acceptable vehicle, **the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent** or a pharmaceutically acceptable addition salt thereof **and a physiologically effective dose of an orgasm-delaying agent** or a pharmaceutically acceptable addition salt thereof.”

17. The sexual therapy formulation as recited in claim 16, wherein said therapeutically effective amount of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(-) isomer of 3,4-methylenedioxymethamphetamine, or said racemic mixture of 3,4-methylenedioxymethamphetamine is about 30

6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.

<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=112151>

DOSE:			
T+ 0:00	100 mg	oral	Pharms - Sildenafil (pill / tablet)
T+ 1:00	80 mg	oral	MDMA (powder / crystals)
T+ 3:00	80 mg	oral	MDMA (powder / crystals)

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.

<https://web.archive.org/web/20070607024945/https://erowid.org/experiences/exp.php?ID=21223>

milligrams to about 125 milligrams.

The screenshot shows a web browser displaying an Erowid experience page. The URL is https://erowid.org/experiences/exp.php?ID=21223. The page title is 'Foxy Sextasy' by Lingamyoni, listing ingredients: MDMA, 5MeO-DIPT, & Sildenafil (Viagra). A table of doses is shown with the following entries:

DOSE:	Amount	Route	Substance	Form
T+ 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DIPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.

<https://web.archive.org/web/20190222023609/https://erowid.org/experiences/exp.php?ID=104048>

The screenshot shows a web browser displaying an Erowid experience page. The URL is https://erowid.org/experiences/exp.php?ID=104048. The page title is 'To Treat Premature Ejaculation'. A table of doses is shown with the following entries:

DOSE:	Amount	Route	Substance	Form
	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.**”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **varденаfil**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

From **claim 10** “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: **3,4-methylenedioxymethamphetamine**, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”

From **page 2** “According to an embodiment of the invention, there is provided a **pharmaceutical composition** in a pharmaceutically acceptable vehicle, **the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent** or a pharmaceutically acceptable addition salt thereof **and a physiologically effective dose of an orgasm-delaying agent** or a pharmaceutically acceptable addition salt thereof.”

**18.** The sexual therapy formulation as recited in claim 14, wherein said libido stimulation component consists of an amount of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, or said racemic mixture of 3,4-methylenedioxymethamphetamine.

6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.

<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=112151>

DOSE:	Amount	Route	Drug Name	Form
T+ 0:00	100 mg	oral	Pharms - Sildenafil	pill / tablet
T+ 1:00	80 mg	oral	MDMA	powder / crystals
T+ 3:00	80 mg	oral	MDMA	powder / crystals

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.

<https://web.archive.org/web/20070607024945/https://erowid.org/experiences/exp.php?ID=21223>

https://erowid.org/experiences/exp.php?ID=21223

271 captures

7 Jun 2007 - 23 Apr 2022

Against the drug war but not sure what to do about  
Join Erowid and help ensure that people have accurate info

2006 2007 2008 About this capture

**Foxy Sextasy**  
MDMA, 5MeO-DIPT, & Sildenafil (Viagra)  
by Lingamyoni

DOSE: T+ 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DIPT	(powder / crystals)

8. MOONDO (2014) "To Treat Premature Ejaculation" Retrieved 22 February 2019.

<https://web.archive.org/web/20190222023609/https://erowid.org/experience/s/exp.php?ID=104048>

https://erowid.org/experiences/exp.php?ID=104048

26 captures

22 Feb 2018 - 23 Apr 2022

2018 2019 2020 About this capture

DOSE:	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

19. The sexual therapy formulation as recited in claim 18, wherein a unit dosage of said formulation comprises a therapeutically effective amount of said libido stimulation component consisting of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, or said racemic mixture of 3,4-methylenedioxymethamphetamine.

6. VSJOE (2018) "Finally, I Was Also Able to Orgasm" Retrieved 8 February 2019.

<https://web.archive.org/web/20190208014713/https://erowid.org/experience/s/exp.php?ID=112151>

https://erowid.org/experiences/exp.php?ID=112151

174 captures

8 Feb 2019 - 7 Jul 2022

2018 2019 2020 About this capture

DOSE: T+ 0:00	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:00	80 mg	oral	MDMA	(powder / crystals)
T+ 3:00	80 mg	oral	MDMA	(powder / crystals)

7. LINGAMYONI (2003) "Foxy Sextasy" Retrieved 7 June 2007.

<https://web.archive.org/web/20070607024945/https://erowid.org/experience/s/exp.php?ID=21223>

https://erowid.org/experiences/exp.php?ID=21223

271 captures

Against the drug war but not sure what to do about  
Join Erowid and help ensure that people have accurate info

7 Jun 2007 - 23 Apr 2022

Go

MAY JUN AUG

07

2006 2007 2008

About this capture

Foxy Sextasy  
MDMA, 5MeO-DIPT, & Sildenafil (Viagra)  
by Lingamyoni

DOSE: T+ 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DIPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.

<https://web.archive.org/web/20190222023609/https://erowid.org/experiences/exp.php?ID=104048>

https://erowid.org/experiences/exp.php?ID=104048

26 captures

22 Feb 2018 - 23 Apr 2022

Go

JAN FEB MAR

22

2018 2019 2020

About this capture

DOSE:	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.**”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **vardenafil**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

From **claim 10** “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: **3,4-methylenedioxymethamphetamine**, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”

From **page 2** “According to an embodiment of the invention, there is provided a **pharmaceutical composition** in a pharmaceutically acceptable vehicle, **the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent** or a pharmaceutically acceptable addition salt thereof **and a physiologically effective dose of an orgasm-delaying agent** or a pharmaceutically acceptable addition salt thereof.”

20. The sexual therapy formulation as recited in claim 19, wherein said therapeutically effective amount of 3,4-methylenedioxymethamphetamine, said R(-) isomer of 3,4-methylenedioxymethamphetamine, said S(+) isomer of 3,4-methylenedioxymethamphetamine, or said racemic mixture of 3,4-methylenedioxymethamphetamine is about 30 milligrams to about 125 milligrams.

6. VSJOE (2018) “Finally, I Was Also Able to Orgasm” Retrieved 8 February 2019.

<https://web.archive.org/web/20190208014713/https://erowid.org/experiences/exp.php?ID=112151>

DOSE:				
T+ 0:00	100 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:00	80 mg	oral	MDMA	(powder / crystals)
T+ 3:00	80 mg	oral	MDMA	(powder / crystals)

7. LINGAMYONI (2003) “Foxy Sextasy” Retrieved 7 June 2007.

<https://web.archive.org/web/20070607024945/https://erowid.org/experiences/exp.php?ID=21223>

https://erowid.org/experiences/exp.php?ID=21223

271 captures

7 Jun 2007 - 23 Apr 2022

Against the drug war but not sure what to do about  
Join Erowid and help ensure that people have accurate info

JUN 07 2007

AUG 2008

About this capture

### Foxy Sextasy

MDMA, 5MeO-DIPT, & Sildenafil (Viagra)  
by Lingamyoni

DOSE: T+ 0:00	125 mg	oral	MDMA (Ecstasy)	(powder / crystals)
T+ 0:00	50 mg	oral	Pharms - Sildenafil	(pill / tablet)
T+ 1:30	25 mg	oral	5-MeO-DIPT	(powder / crystals)

8. MOONDO (2014) “To Treat Premature Ejaculation” Retrieved 22 February 2019.

<https://web.archive.org/web/20190222023609/https://erowid.org/experiences/exp.php?ID=104048>

https://erowid.org/experiences/exp.php?ID=104048

26 captures

22 Feb 2019 - 23 Apr 2022

JAN 2019

FEB 22 2019

MAR 2020

About this capture

DOSE:	3 glasses	oral	Alcohol - Beer/Wine	
	60 mg	oral	MDMA	(powder / crystals)
	60 mg	oral	MDMA	(powder / crystals)
	25 mg	oral	Pharms - Sildenafil	(pill / tablet)
	3 glasses	oral	Alcohol - Beer/Wine	
	50 mg	oral	Pharms - Sildenafil	(pill / tablet)

9. Int’l Pat. App. Pub. No. WO/2020/006606 “A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME” (Published January 9, 2020)

From **Abstract** “The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof. **The disclosed pharmaceutical composition may be useful in the treatment of erectile dysfunction and premature ejaculation.**”

From **claim 1** “A pharmaceutical composition in a pharmaceutically acceptable vehicle, the pharmaceutical composition comprising a physiologically effective, non- priapismic, **dose of a penile-erection-inducing agent or a pharmaceutically acceptable addition salt thereof and a physiologically effective dose of an orgasm-delaying agent or a pharmaceutically acceptable addition salt thereof.**”

From **claim 3** “The composition of claim 2, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of: **avanafil**, iodenafil, mirodenafil, **sildenafil**, **tadalafil**, **vardenafile**, udenafil, zaprinast, icariin, benzamidenafil, and dasantafil.”

From **claim 4** “The composition according to any one of claims 1 to 3, wherein the orgasm delaying agent is selected from the group consisting of: anaesthetics, analgesics, antidepressants, sedatives, and stimulants.”

From **claim 10** “The composition according to claim 4, wherein the stimulant is selected from the group consisting of: **3,4-methylenedioxymethamphetamine**, amphetamine, caffeine, ephedrine, mephedrone, methylenedioxypropylvalerone, methylphenidate, nicotine, /N-methyl-alpha-methylphenethylamine, phenylpropanolamine, propylhexedrine, and pseudoephedrine.”

From **page 2** “According to an embodiment of the invention, there is provided a **pharmaceutical composition** in a pharmaceutically acceptable vehicle, **the pharmaceutical composition comprising a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent** or a pharmaceutically acceptable addition salt thereof **and a physiologically effective dose of an orgasm-delaying agent** or a pharmaceutically acceptable addition salt thereof.”



## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	46251714
<b>Application Number:</b>	17525248
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3168
<b>Title of Invention:</b>	SEXUAL THERAPY FORMULATION AND METHOD OF TREATMENT
<b>First Named Inventor/Applicant Name:</b>	Bjorn Erik Hansen
<b>Customer Number:</b>	106452
<b>Filer:</b>	Shahin Shams
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	7782.0200
<b>Receipt Date:</b>	22-JUL-2022
<b>Filing Date:</b>	12-NOV-2021
<b>Time Stamp:</b>	13:53:45
<b>Application Type:</b>	

### Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$90
RAM confirmation Number	E20227LD53421739
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

--	--	--	--	--	--

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Concise Description of Relevance	Concise-description-generated.pdf	48061	no	9
			57251bcc8859686b9fc5e4d4e242e8b86ffb1c3a		

**Warnings:**

**Information:**

2	Third-Party Submission Under 37 CFR 1.290	Third-party-preissuance-submission.pdf	72906	no	5
			a4cd660312166e664b7aafa18f8097c33b0a8bc31		

**Warnings:**

**Information:**

3	Request for Notification of Non-compliant Third-Party Submission	Third-party-notification-request.pdf	23720	no	1
			ddc9dd961b64cff333dfffeac49d14acc581b6e3		

**Warnings:**

**Information:**

4	Evidence of Publication	1-HALKITIS.pdf	73236	no	9
			2e3c7aad65b051984b3407b89c4eeacbe432e40b		

**Warnings:**

**Information:**

5	Evidence of Publication	2-McMURRAY.pdf	207195	no	8
			08516ca275d7bad7a54f53aa653b6b8e26147636		

**Warnings:**

**Information:**

6	Evidence of Publication	3-SMITH.pdf	495819	no	13
			6c5ad5f167b9d3b0c8d51c4cbad96553099c3e7b		

**Warnings:**

**Information:**

--	--	--	--	--	--

7	Evidence of Publication	4-BAHJI.pdf	6456158	no	30
			ceb341bcfcef68cfce4c8341a6ebb36fb9311de		
<b>Warnings:</b>					
<b>Information:</b>					
8	Evidence of Publication	5-OBLIVION.pdf	1513427	no	4
			8e69b7745aeec3c3bbef35caf7baa400712dc880		
<b>Warnings:</b>					
<b>Information:</b>					
9	Evidence of Publication	6-VSJOE.pdf	370007	no	1
			88f2a60ecfbc1b063bd39a64f655d6305e95e9db		
<b>Warnings:</b>					
<b>Information:</b>					
10	Evidence of Publication	7-LINGAMYONI.pdf	270138	no	1
			d705ffdb592b26c9cfd1b68ab5896f46c4076d50		
<b>Warnings:</b>					
<b>Information:</b>					
11	Evidence of Publication	8-MOONDO.pdf	390023	no	1
			8fcc8a51b89cbe478e33cb8fe77a682278532b97		
<b>Warnings:</b>					
<b>Information:</b>					
12	Evidence of Publication	9-WO2020006606A1.pdf	1148023	no	24
			321fbeatb694d8f6177630ce45202ccdde4648ad		
<b>Warnings:</b>					
<b>Information:</b>					
13	Concise Description of Relevance	US20220152032ClaimChartCompany.pdf	325615	no	32
			4baa78cea86d6e3dc40ba5d9e101b97d762f7856		
<b>Warnings:</b>					
<b>Information:</b>					

14	Fee Worksheet (SB06)	fee-info.pdf	37348  b2c3287ba6299c1570779a8c38cbb8c30cfa7cad	no	2
----	----------------------	--------------	---	----	---

**Warnings:**

**Information:**

<b>Total Files Size (in bytes):</b>	11431676
-------------------------------------	----------

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**